Lifesci Capital Comments on Perspective Therapeutics Q2 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Investment analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Perspective Therapeutics in a note issued to investors on Tuesday, May 12th. Lifesci Capital analyst O. Mccammon expects that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.27) EPS.

A number of other equities analysts have also commented on CATX. Piper Sandler began coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Truist Financial set a $12.00 target price on Perspective Therapeutics in a report on Tuesday, March 17th. Royal Bank Of Canada decreased their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, March 17th. Finally, HC Wainwright boosted their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.77 on Wednesday. The business’s 50-day moving average price is $4.47 and its 200-day moving average price is $3.59. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.17 and a quick ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative return on equity of 47.18% and a negative net margin of 17,982.69%.The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CATX. Russell Investments Group Ltd. raised its stake in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after buying an additional 5,475 shares during the last quarter. Aigen Investment Management LP bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $28,000. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $31,000. Abel Hall LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $49,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.